Critical Contrast: Pharmacyte Biotech

Critical Contrast: Pharmacyte Biotech


Pharmacyte Biotech and FitLife Brands are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Pharmacyte Biotech has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500.



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога